Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Completed · Early Phase 1
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage III breast cancer.
Key facts
- Study ID
- NCT00331630
- Run by
- Northwestern University
- People needed
- 30
- Starts
- 2006-05-04
- Expected to finish
- 2010-08-05
- Last updated by the study team
- 2020-03-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University, Northwestern Medical Faculty Foundation — Chicago, Illinois, United States
- Hematology-Oncology Associates of Illinois — Chicago, Illinois, United States
- Midwest Center for Hematology/Oncology — Joliet, Illinois, United States
- Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields — Olympia Fields, Illinois, United States
- Joe Arrington Cancer Research and Treatment Center — Lubbock, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.